Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 152

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 152
---
us Directive), as permitted 
 under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or                       |

| ● | in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such                               
 offer of securities shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of 
 the Prospectus Directive.                                                                                                               |

For the purposes of this provision,
the expression an “offer to the public” in relation to any securities in any Relevant Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor
to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive
in that Member State, the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including
the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure
in the Relevant Member State, and the expression “2010 PD Amending Directive” means Directive 2010/73/EU.

Israel. This
document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with
or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only
at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities
Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment
advisors, members of the Tel Aviv Stock Exchange, placement agents, venture capital funds, entities with equity in excess of NIS 50 million
and “qualified individuals”, each as defined in the Addendum (as it may be amended from time to time), collectively referred
to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their
clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall
within the scope of the Addendum, are aware of the meaning of same and agree to it.

United Kingdom.
Each placement agent